{"organizations": [], "uuid": "a2e6575278d4891ba604dac65db6affea8fa082e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lexicon-announces-regulatory-submi/brief-lexicon-announces-regulatory-submissions-for-sotagliflozin-to-treat-adults-with-type-1-diabetes-idUSFWN1R80MF", "country": "US", "domain_rank": 408, "title": "BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T14:49:00.000+03:00", "replies_count": 0, "uuid": "a2e6575278d4891ba604dac65db6affea8fa082e"}, "author": "", "url": "https://www.reuters.com/article/brief-lexicon-announces-regulatory-submi/brief-lexicon-announces-regulatory-submissions-for-sotagliflozin-to-treat-adults-with-type-1-diabetes-idUSFWN1R80MF", "ord_in_thread": 0, "title": "BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes", "locations": [], "entities": {"persons": [{"name": "sotaglif", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters) - lexicon pharmaceuticals inc", "sentiment": "none"}, {"name": "sanofi", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26, 2018 / 11:51 AM / in 6 minutes BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes Reuters Staff March 26 (Reuters) - Lexicon Pharmaceuticals Inc: * LEXICON PHARMACEUTICALS ANNOUNCES REGULATORY SUBMISSIONS FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES * LEXICON PHARMA - SANOFI SUBMITTED NDA TO FDA FOR SOTAGLIFLOZIN COMBINED WITH INSULIN THERAPY TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 1 DIABETES Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T14:49:00.000+03:00", "crawled": "2018-03-26T15:03:40.003+03:00", "highlightTitle": ""}